Probiotics enhance the effect of allergy immunotherapy on regulating antigen specific B cell activity in asthma patients.

Abstract

Immune regulatory system dysfunction plays a role in the pathogenesis of asthma. The therapeutic effect of allergic asthma is to be improved. The immune regulatory function of probiotics has been recognized. This study tests a hypothesis that Clostridium butyricum (CB) enhances the effect of allergen specific immunotherapy (AIT) on asthma. In this study patients with allergic asthma were treated with AIT or/and CB for six months. The therapeutic effect and IgE production of the patients were observed. The results showed that administration with AIT alone alleviated the asthma symptoms; but the serum levels of interleukin (IL)-4, IL-5, IL-13 and specific IgE were not altered, which was markedly improved by the administration with CB plus AIT. Such effects were maintained only for two months in the patients treated with AIT alone; but maintained more than 12 months in those patients treated with both AIT and CB. CB facilitated AIT to induce IL-10+ B cells (B10 cells) in asthma patients. AIT/CB therapy converted antigen specific B cells to antigen specific regulatory B cells. Butyrate modulated the gene transcription of IgE and IL-10 in the allergen specific B cells. In conclusion, administration of CB can enhance the therapeutic effect of AIT in the treatment of allergic asthma via facilitating generation of B10 cells.

• Authors: Jun Liu, Feng-Hong Chen, Shu-Qi Qiu, Li-Tao Yang, Huan-Ping Zhang, Jiang-Qi Liu, Xiao-Rui Geng, Gui Yang, Zhi-Qiang Liu, Jing Li, Zhi-Gang Liu, Hua-Bin Li, Ping-Chang Yang
• Journal: American journal of translational research (Am J Transl Res) Vol. 8 Issue 12 Pg. 5256-5270 ( 2016) ISSN: 1943-8141 [Print] United States
• PMID: 28078000 (Publication Type: Journal Article)